Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-12-13
DOI
10.1038/s41598-019-54204-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid
- (2019) Valeria Lifke et al. CLINICAL BIOCHEMISTRY
- Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging
- (2018) Suzanne E. Schindler et al. Alzheimers & Dementia
- CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts
- (2018) Oskar Hansson et al. Alzheimers & Dementia
- Abnormal Hyperphosphorylation of Tau: Sites, Regulation, and Molecular Mechanism of Neurofibrillary Degeneration
- (2018) Jian-Zhi Wang et al. JOURNAL OF ALZHEIMERS DISEASE
- Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic
- (2018) Harald Hampel et al. Nature Reviews Neurology
- Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer’s dementia
- (2017) Lutz Frölich et al. Alzheimers Research & Therapy
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment
- (2017) Shorena Janelidze et al. JAMA Neurology
- Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years
- (2017) Joakim Hertze et al. JOURNAL OF ALZHEIMERS DISEASE
- Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid
- (2016) Tobias Bittner et al. Alzheimers & Dementia
- Alzheimer's disease
- (2016) Philip Scheltens et al. LANCET
- A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
- (2016) Clifford R. Jack et al. NEUROLOGY
- Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis
- (2016) Niklas Mattsson et al. Nature Communications
- Alzheimer’s Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans
- (2015) Paul S. Aisen et al. Alzheimers & Dementia
- Neuropathologic assessment of participants in two multi-center longitudinal observational studies: The Alzheimer Disease Neuroimaging Initiative (ADNI) and the Dominantly Inherited Alzheimer Network (DIAN)
- (2015) Nigel J. Cairns et al. NEUROPATHOLOGY
- Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
- (2014) P M Doraiswamy et al. MOLECULAR PSYCHIATRY
- Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later
- (2013) C. M. Roe et al. NEUROLOGY
- Fluid Biomarkers in Alzheimer Disease
- (2013) K. Blennow et al. Cold Spring Harbor Perspectives in Medicine
- Clinical and multimodal biomarker correlates of ADNI neuropathological findings
- (2013) Jon B Toledo et al. Acta Neuropathologica Communications
- Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia
- (2012) Peder Buchhave ARCHIVES OF GENERAL PSYCHIATRY
- A European multicentre PET study of fibrillar amyloid in Alzheimer’s disease
- (2012) Agneta Nordberg et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
- (2010) Kaj Blennow et al. Nature Reviews Neurology
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
- (2009) Leslie M. Shaw et al. ANNALS OF NEUROLOGY
- CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
- (2009) Niklas Mattsson JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study
- (2009) Pieter Jelle Visser et al. LANCET NEUROLOGY
- Conversion of amyloid positive and negative MCI to AD over 3 years: An 11C-PIB PET study
- (2009) A. Okello et al. NEUROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now